课题基金 / 基金详情

ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM

ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM
ACTG353 口服奈非那韦联合齐多夫定
批准号：
6306584
负责人：
MARGARET A KELLER
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6306584
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research clinical trial phase I combination chemotherapy female human pregnant subject human subject human therapy evaluation lamivudine protease inhibitor vertical transmission zidovudine

项目摘要

项目成果

MARGARET A KELLER的其他基金

相似基金

相关文献

中文摘要
翻译
观察一种名为奈非那韦的新药与齐多夫定和拉米夫定联合使用对感染艾滋病毒的孕妇及其婴儿的影响。这将是首次在孕妇身上进行这项研究。看看服用这种组合是否会进一步降低婴儿感染艾滋病毒的风险。
英文摘要
To look at effects of giving a new medicine called nelfinavir in combination with Zidovudine and Lamivudine to HIV infected pregnant women and their babies. This will be the first time this will be studied in pregnant women. To see if taking this combination will further reduce the risk of HIV infection to the baby.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY
海外基金